AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 43% of AstraZeneca‘s total revenues) rose 18% in the second quarter of 2025, generating $6.3 ...

AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...

With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in ...

On Friday, AstraZeneca Plc AZN released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as a perioperative treatment for patients with resectable Stage II-IVA ...

Imfinzi is a major revenue driver for AstraZeneca, generating around $4.7bn in sales in 2024. Its European label covers a range of cancers, including lung, biliary tract, and liver, amongst others.

AstraZeneca strives to redefine cancer care and help transform outcomes for patients with IMFINZI as a monotherapy and in combination with IMJUDO as well as other novel immunotherapies and modalities.

FDA grants Priority Review to AstraZeneca’s Imfinzi sBLA for muscle-invasive bladder cancer, with decision expected in Q2 2025. Imfinzi regimen showed a 32% reduced risk of disease progression ...

AstraZeneca AZN announced that the FDA has approved its blockbuster cancer drug Imfinzi (durvalumab) for treating limited-stage small cell lung cancer (LS-SCLC) in adult patients whose disease has ...

AstraZeneca’s (AZN) Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell lung cancer, LS-SCLC, whose disease has not ...

(RTTNews) - British drug major AstraZeneca Plc (AZN, AZN.L) announced Monday that its Imfinzi (durvalumab) has been approved in the European Union as first and only immunotherapy for limited-stage ...